Multicolor IF analysis revealed elevated expression of key enzymes associated with glucose and lipid metabolism (GLUT1 for glucose transport; FASN for fatty acid synthesis; CD36 and FABPs for fatty acid transport) in resistant tumor tissues compared with parental cells, which was unaffected by lenvatinib treatment, indicating metabolic reprogramming in resistant tumors (Fig. 1e, f). Here, FASN is linked to neoplasm.